Eurofins reports Q3 2019 revenues increased 22.3% year-on-year to EUR 1,167m vs. EUR 955m in Q3 2018.

Posted by Mark Balbach on Nov 5, 2019, 8:00:00 AM

Eurofins Central Laboratory is a member of Eurofins BioPharma Services, a division of Eurofins Scientific, (hereinafter sometimes “Eurofins” or “the Group”). As a member of the Group, we are pleased to release to you our Q3 2019 earnings. Over the first nine months of 2019, total revenues grew 23.6% to EUR 3,335m vs. EUR 2,698m during the same period last year. Eurofins continues to express strong organic growth of 6.4% reported in Q3 2019. In Western Europe and North America, Eurofins BioPharma Services continued to perform exceptionally, with a double digit organic growth in Q3 2019 thanks to sustained, above market and overall growth as strategic outsourcing remains strong in the biopharmaceutical industry.

Read More

Tags: Central Laboratory, Quality, Results, Drug Development, Development, Science Education, BioPharma

Brexit Status Update - September 23rd, 2019

Posted by Sandra Hageman on Sep 24, 2019, 2:19:27 PM

37 Days and Counting...

As the new Brexit deadline of 31 October 2019 nears, the UK government and EU leaders are still negotiating and discussing a mutual agreement for Brexit. The EU maintains its standpoint to not allow a Brexit deal which may break the Good Friday peace deal between Northern Ireland and the Republic of Ireland. The UK on the other hand, has vowed to remove the backstop, and has not yet provided a clear solution on how potential issues at the above mentioned border would be solved.

Read More

Tags: Central Laboratory, Brexit

Cancer is Tough. The Quiet Hero is Tougher.

Posted by Jesse Gehris on Sep 20, 2019, 3:10:14 PM

Prevention and Treatment of Cancer is the Most Significant Topic of the 21st Century

In 2018, there were 18 million reported cancer cases worldwide. This month, our Quiet Heroes behind the scenes at Eurofins Central Laboratory stand with the Leukemia & Lymphoma Society in recognizing September as Blood Cancer Awareness Month. Some of these cancers include:

Read More

Tags: Central Laboratory, Quality, Clinical Trial, Drug Development, Development, BioPharma, Cancer, Blood Cancer

The Quiet Hero & World Hepatitis Day

Posted by Jesse Gehris on Jul 28, 2019, 8:00:00 AM

The largest internal organ in the human body is the liver. The liver aids in digestion, energy storage, removal of toxins from the body, and supports many other functions. Because of the important job requirements set forth for this internal organ, evolution has assured us complete regeneration, so long as 25% of the tissue remaining is healthy.

Read More

Tags: Central Laboratory, Clinical Trial, Drug Development, Bioanalytical Testing, Development, BioPharma, Liver, Hepatitis

Join Eurofins at the 2019 DIA Annual Meeting in San Diego, CA

Posted by Jesse Gehris on Jun 3, 2019, 9:15:00 AM

Eurofins BioPharma Services will be attending the DIA Global Annual Meeting in San Diego, CA, June 23-27! Join us at Booth 1705 to discover how our dedicated BioPharma laboratories provide seamless, end-to-end solutions to help customers progress through the drug development cycle through a single, experienced provider!

Read More

Tags: Central Laboratory, Quality, Clinical Trial, Drug Development, Development, BioPharma, Gene Therapy

Eurofins Achieves 2019 CRO Leadership Award

Posted by Jesse Gehris on May 30, 2019, 9:00:00 AM

For the 2019 CRO Leadership Awards, Life Science Leader magazine once again teamed up with Industry Standard Research (ISR) to determine the award recipients. More than 60 contract research organizations were assessed on over 20 performance metrics in ISR's annual CRO Quality Benchmarking survey. Eurofins is recognized as a recipient of these awards, exceeding customer expectations in every category.

Read More

Tags: Central Laboratory, Quality, Results, Drug Development, Development, BioPharma

FDA Efforts in Advancing Development of Gene Therapy

Posted by Brian Wile on May 24, 2019, 9:25:52 AM

With Dr. Marks’ (Director, Center for Biologics Evaluation and Research), recent perspective on FDA’s Effort to Advance the Development of Gene Therapy, he thoughtfully highlights the recent successes of approved gene therapies, highlights the expert resourcing within FDA, CBER and NIH being applied towards this therapeutic specialization and details the innovative programs and committees (Novel and Exceptional Technology and Research Advisory Committee (NExTRAC), Regenerative Medicine Advanced Therapy (RMAT) designation and the INTERACT program) being instituted and enacted by the FDA.  In addition, he highlights the critical issue facing success of this scientific endeavor, is quality manufacturing capacity but attentively details FDA action of awarding grants dedicated to industry stakeholders for the advancement of manufacturing technologies.

Read More

Tags: FDA, Results, Drug Development, Cellular Response, Development, DNA, Gene Therapy

Join Eurofins at the 2019 BIO Annual International Convention

Posted by Jesse Gehris on May 10, 2019, 9:00:00 AM

Eurofins BioPharma Services will be attending the 2019 BIO International Convention in Philadelphia, June 3-6, to celebrate the globally important innovations in biotech that start with one: one meeting, one theory, one trial, one breakthrough. Join Eurofins BioPharma Services at Booth 2949 to consider how the largest wholly-owned network of BioPharma dedicated laboratories in the world can assist in your clinical trial research!

Read More

Tags: Central Laboratory, Quality, Results, Clinical Trial, BioPharma

Brexit Status Update - April 11, 2019

Posted by Sandra Hageman on Apr 11, 2019, 11:28:33 AM

 

Update - April 11th, 2019

 

Read More

Tags: Central Laboratory, Clinical Trial, Brexit

Brexit - What's Next?

Posted by Sandra Hageman on Mar 29, 2019, 9:28:23 AM

 

Update - March 29th, 2019

Last week, the United Kingdom (UK) and European Union (EU) reached an agreement on a postponement of the Brexit after ample discussions. As a result, the Brexit will not occur on Friday, March 29, 2019 as originally planned.

Actually today, March 29th, 2019, on the day the UK was due to leave the EU, MPs will have a third vote on the Withdrawal Agreement - the legally binding document that sets out the terms of the UK's departure from the EU. This includes a settlement, details of a transition period for after the UK leaves and protections for citizens' rights. It also includes the controversial backstop, or the insurance policy that aims to prevent a hard border returning to the island of Ireland.

Read More

Tags: Central Laboratory, Clinical Trial, Brexit